Celcuity is like a **Foundation Medicine** for live tumor cells, using its CELsignia platform to identify the specific cellular processes driving a patient's cancer and match them with the most effective targeted therapy.

• CELsignia Diagnostic Platform: A diagnostic platform that analyzes living tumor cells to identify specific abnormal cellular processes and guide targeted therapy selection for cancer patients.
• Gedatolisib: A drug candidate, a PI3K/mTOR inhibitor, in development for the treatment of advanced or metastatic breast cancer.
• CELsignia MP Test: A qualitative laboratory developed test measuring HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells.

Celcuity (CELC) is a clinical-stage biotechnology company focused on developing molecularly targeted therapies and diagnostic tests for cancer patients. Given its stage of development, the company's products are not yet widely commercialized for direct sales to individual patients. Instead, its major customers would typically be other companies, strategic partners, or healthcare institutions for licensing, development, or future commercialization.

Based on the provided information, the company has had a significant customer relationship with:

• Pfizer, Inc. (PFE) - Celcuity had a license agreement with Pfizer for the development and commercialization rights to its drug candidate, Gedatolisib. This type of licensing arrangement signifies that Pfizer was a major customer, acquiring rights to Celcuity's intellectual property and drug candidate.

• Catalent, Inc. (CTLT)
• Pfizer Inc. (PFE)

Brian Sullivan, Chief Executive Officer and Co-founder

Brian Sullivan has over 25 years of experience founding and building successful technology companies. He was Chairman and CEO of Sterilmed, a medical device company, from 2003 until its sale to Johnson & Johnson for $330 million in 2011. Previously, he co-founded and served as CEO of Recovery Engineering, a filtration company that he took public and subsequently sold to Procter & Gamble for $265 million in 1999. He has received 11 U.S. patents.

Vicky Hahne, Chief Financial Officer

Vicky Hahne brings over 20 years of financial leadership experience, including extensive work in the healthcare industry.

Lance Laing, PhD, Chief Science Officer and Co-founder

Lance Laing is a co-founder of Celcuity and has a career spanning more than 30 years in drug discovery research and technology development. He received his doctorate in biophysics and biochemistry from Johns Hopkins University. He has received multiple U.S. and international patents. His drug discovery research career began at Scriptgen/Anadys Pharmaceuticals (purchased by Novartis).

Igor Gorbatchevsky, MD, Chief Medical Officer

Igor Gorbatchevsky has over two decades of hands-on oncology drug development experience, including successful regulatory IND and NDA/BLA filings across several drug classes. Prior to joining Celcuity, he held leadership roles in clinical development at MEI Pharma, Iovance Biotherapeutics, Bayer Pharmaceuticals, and Daiichi-Sankyo. He received his MD and PhD in cell biology from Baylor College of Medicine.

Eldon Mayer, Chief Commercial Officer

Eldon Mayer serves as the Chief Commercial Officer for Celcuity.

The key risks for Celcuity (CELC), a clinical-stage biotechnology company, primarily revolve around the successful development, regulatory approval, and commercialization of its lead drug candidate, gedatolisib.

1. Regulatory Approval and Commercialization Challenges: Celcuity's immediate future and valuation are heavily dependent on the U.S. Food and Drug Administration's (FDA) approval of gedatolisib, particularly with a Prescription Drug User Fee Act (PDUFA) target date of July 17, 2026. The company's stock is currently "priced for perfection," meaning any delays, additional clinical requirements, or a denial of approval could lead to a substantial decrease in share value. Even if gedatolisib receives regulatory approval, successful commercialization and broad market acceptance are not guaranteed, especially within the highly competitive oncology market where numerous existing treatment options are available to physicians and patients. There is also a risk that post-marketing trials might not confirm clinical benefits, potentially leading to a withdrawal of approval.
2. Single-Asset Dependency: Celcuity's financial health and overall prospects are almost entirely tied to the success of its lead drug candidate, gedatolisib. While the company has other pipeline initiatives, such as the PIK3CA mutant cohort of the VIKTORIA-1 trial and prostate cancer trials, gedatolisib for HR+/HER2- advanced or metastatic breast cancer represents the most advanced and significant near-term catalyst. A failure of gedatolisib to secure approval or achieve market penetration would severely impact the company's outlook and stock performance.
3. Financial Sustainability and Cash Burn: As a clinical-stage biotechnology company, Celcuity currently generates no revenue and incurs a high cash burn rate to fund its research and development (R&D) activities and prepare for potential commercialization. Although Celcuity reported a strong cash position of approximately $455 million as of the third quarter of 2025, which has mitigated short-term financing risks, the increasing costs associated with transitioning to commercial operations are notable. Long-term financial sustainability hinges on generating significant revenue from gedatolisib; a failure to do so could necessitate future dilutive equity raises.

Celcuity Inc. (CELC) focuses on molecularly targeted therapies and diagnostics for cancer patients. The addressable markets for its main products and services are as follows:

Gedatolisib

Celcuity's drug candidate, Gedatolisib, targets hormone receptor-positive (HR+), HER2-negative (HER2-), advanced or metastatic breast cancer, particularly in the second-line setting after patients have progressed on a CDK4/6 inhibitor.

• The estimated addressable market for Gedatolisib in the second-line setting for HR-positive, HER2-negative advanced breast cancer is between $5 billion to $6 billion in the U.S.
• Celcuity projects potential peak revenues for Gedatolisib in this indication to be $2.5 billion to $3 billion.
• Approximately 37,000 patients in the U.S. with HR-positive, HER2-negative advanced breast cancer who have progressed after treatment with a CDK4/6 inhibitor constitute the estimated addressable patient population for Gedatolisib.

CELsignia Diagnostic Platform / CELsignia MP Test

The CELsignia diagnostic platform and CELsignia MP test are designed to identify abnormal cellular processes and measure HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells.

• The global breast cancer diagnostics market size was valued at approximately USD 20.14 billion in 2025 and is projected to reach around USD 40.71 billion by 2034. North America held the largest share of this market, at 45.77% in 2024.
• The global ovarian cancer diagnostics market size was valued at approximately USD 1.54 billion in 2023 and is projected to reach USD 2.71 billion by 2032. Another estimate places the global market at USD 1.74 billion in 2024, expected to grow to USD 3.11 billion by 2033. North America accounted for the largest revenue share in the ovarian cancer diagnostics market, at 41.2% in 2023.

Here are the expected drivers of future revenue growth for Celcuity (CELC) over the next 2-3 years:

1. Commercialization of Gedatolisib for HR+/HER2- Advanced Breast Cancer: The primary driver of revenue growth is the anticipated commercial launch of Gedatolisib for hormone receptor-positive, HER2-negative, PIK3CA wild-type advanced breast cancer. The U.S. Food and Drug Administration (FDA) has granted Priority Review for Celcuity's New Drug Application (NDA) for Gedatolisib, with a Prescription Drug User Fee Act (PDUFA) decision date set for July 2026. This follows positive efficacy and safety results from the Phase 3 VIKTORIA-1 trial, which showed a substantial reduction in the risk of disease progression or death for patients. Management has projected potential peak revenues of $2.5 billion to $3 billion for this indication.
2. Expansion of Gedatolisib into Additional Indications: Celcuity is actively pursuing the expansion of Gedatolisib into new patient populations and cancer types. This includes the ongoing Phase 3 VIKTORIA-2 clinical trial, evaluating Gedatolisib as a first-line treatment for patients with HR+/HER2- advanced breast cancer. Additionally, a Phase 1/2 clinical trial (CELC-G-201) is evaluating Gedatolisib in combination with darolutamide for patients with metastatic castration-resistant prostate cancer. Successful development and regulatory approval for these expanded indications would significantly broaden the addressable market and drive subsequent revenue growth.
3. International Market Expansion for Gedatolisib: Beyond the U.S. market, Celcuity plans to expand the commercialization of Gedatolisib internationally. The company is pursuing regulatory approvals in Europe and Japan, with a potential European Union (EU) approval anticipated by late 2027. This strategic geographic expansion will allow Celcuity to tap into larger global patient populations and generate additional revenue streams from these new markets.
4. Leveraging the CELsignia Diagnostic Platform: Celcuity's proprietary CELsignia diagnostic platform, which identifies specific abnormal cellular processes driving a patient's cancer, is integral to its targeted therapy approach. While current revenue from diagnostic technology is minimal, the CELsignia platform is crucial for identifying patient populations for therapies like Gedatolisib and other pipeline candidates. Future revenue growth could stem from the broader adoption and commercialization of CELsignia tests, such as the CELsignia MP test for breast and ovarian tumor cells, potentially as companion diagnostics or through collaborations that demonstrate its value in personalizing cancer treatment.

Share Repurchases

Celcuity has not made any share repurchases over the last 3-5 years.

Share Issuance

• In July 2025, Celcuity announced proposed public offerings for $150 million in convertible senior notes due 2031 and $75 million in common stock, with options for underwriters to purchase additional amounts.
• In May 2024, the company priced an underwritten offering of 3,871,000 shares of common stock at $15.50 per share, raising $60 million.
• In June 2021, Celcuity completed an underwritten public offering of 2,250,000 shares of common stock at $25.00 per share, generating approximately $56.25 million in gross proceeds.

Inbound Investments

• In September 2025, Celcuity amended its senior secured credit facility with Innovatus Capital Partners, LLC and Oxford Finance LLC, increasing the total term loan facility to $500 million, with $350 million committed and an initial funding of $30 million received.
• Institutional investors, including BVF Partners L.P., Vivo Capital, and Eventide Asset Management, participated in the $60 million common stock offering in May 2024.
• As of November 2025, Avoro Capital Advisors LLC beneficially owned 6.72% of Celcuity's common stock, and Perceptive disclosed a 6.8% stake in February 2026.

Capital Expenditures

• Celcuity's capital expenditures are primarily directed towards research and development (R&D) and clinical trial activities for its lead therapeutic candidate, gedatolisib.
• R&D expenses increased from $60.6 million in 2023 to $104.2 million for the full year 2024.
• Capital expenditures were -$240,878 in the last 12 months, with the company expecting existing cash and borrowings to fund operating and capital expenditure requirements through at least the second half of 2026.